Eli Lilly and Company
CL ˙ SNSE ˙ US5324571083
SecurityCL:LLY / Eli Lilly and Company
InstitutionNicholas Company, Inc.
Latest Disclosed Ownership69,981 shares
Latest Disclosed Value $ 64,366,424
Nicholas Company, Inc. reports 9.50% decrease in ownership of LLY / Eli Lilly and Company

On May 4, 2026 - Nicholas Company, Inc. filed a 13F-HR form disclosing ownership of 69,981 shares of Eli Lilly and Company (CL:LLY) valued at $64,366,424 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 4, 2026 disclosing 77,329 shares of Eli Lilly and Company. This represents a change in shares of -9.50% during the quarter.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-04 2026-03-31 13F Eli Lilly and COM 532457108 69,981 -7,348 -9.50 64,366 -22.55 1.2630
2026-02-04 2025-12-31 13F Eli Lilly and COM 532457108 77,329 -21,185 -21.50 83,104 10.56 1.4555
2025-11-12 2025-09-30 13F Eli Lilly and COM 532457108 98,514 6,500 7.06 75,166 4.79 1.2755
2025-08-05 2025-06-30 13F Eli Lilly and COM 532457108 92,014 7,940 9.44 71,728 3.30 1.2007
2025-05-08 2025-03-31 13F Eli Lilly and COM 532457108 84,074 11,489 15.83 69,438 23.92 1.2024
2025-02-10 2024-12-31 13F Eli Lilly and COM 532457108 72,585 -4,680 -6.06 56,036 -18.14 0.9075
2024-11-12 2024-09-30 13F Eli Lilly and COM 532457108 77,265 -4,510 -5.52 68,452 -7.54 1.1137
2024-07-24 2024-06-30 13F Eli Lilly and COM 532457108 81,775 -2,290 -2.72 74,037 13.21 1.2317
2024-05-14 2024-03-31 13F Eli Lilly and COM 532457108 84,065 -15,020 -15.16 65,399 13.23 1.0807
2024-02-13 2023-12-31 13F Eli Lilly and COM 532457108 99,085 -10 -0.01 57,759 8.51 1.0224
2024-02-13 2023-09-30 13F/A-1 Eli Lilly and COM 532457108 99,095 -13,005 -11.60 53,227 1.24 1.0654
2023-11-13 2023-09-30 13F Eli Lilly and COM 532457108 99,095 -13,005 53,227 1.0654
2024-02-13 2023-06-30 13F/A-2 Eli Lilly and COM 532457108 112,100 0 0.00 52,573 36.56 1.0060
2023-10-31 2023-06-30 13F/A-1 Eli Lilly and COM 532457108 112,100 0 52,573 1.0060
2023-08-08 2023-06-30 13F Eli Lilly and COM 532457108 112,100 0 52,573 1.0060
2024-02-13 2023-03-31 13F/A-1 Eli Lilly and COM 532457108 112,100 0 0.00 38,497 -6.13 0.7810
2023-05-11 2023-03-31 13F Eli Lilly and COM 532457108 112,100 0 38,497 0.7810
2024-02-13 2022-12-31 13F/A-1 Eli Lilly and COM 532457108 112,100 -35 -0.03 41,011 13.11 0.8773
2023-02-09 2022-12-31 13F Eli Lilly and COM 532457108 112,100 -35 41,011 0.8773
2024-02-13 2022-09-30 13F/A-1 Eli Lilly and COM 532457108 112,135 -4,355 -3.74 36,259 -4.00 0.8299
2022-11-14 2022-09-30 13F Eli Lilly and COM 532457108 112,135 -4,355 36,259 0.8299
2024-02-13 2022-06-30 13F/A-1 Eli Lilly and COM 532457108 116,490 -11,745 -9.16 37,770 2.85 0.8249
2022-07-26 2022-06-30 13F Eli Lilly and COM 532457108 116,490 -11,745 37,770 0.8249
2024-02-13 2022-03-31 13F/A-1 Eli Lilly and COM 532457108 128,235 -54,570 -29.85 36,723 -27.27 0.6551
2022-05-11 2022-03-31 13F Eli Lilly and COM 532457108 128,235 -54,570 36,723 0.6551
2022-02-11 2021-12-31 13F Eli Lilly and COM 532457108 182,805 -100 -0.05 50,494 19.48 0.8219
2021-11-15 2021-09-30 13F Eli Lilly and COM 532457108 182,905 -48,175 -20.85 42,260 -20.32 0.7446
2021-08-12 2021-06-30 13F Eli Lilly and COM 532457108 231,080 -100 -0.04 53,037 22.80 0.9318
2021-05-14 2021-03-31 13F Eli Lilly and COM 532457108 231,180 -1,400 -0.60 43,189 9.98 0.8070
2021-02-10 2020-12-31 13F Eli Lilly and COM 532457108 232,580 50,820 27.96 39,269 45.96 0.7435
2020-11-13 2020-09-30 13F Eli Lilly and COM 532457108 181,760 -15,340 -7.78 26,904 -16.86 0.5665
2020-08-13 2020-06-30 13F Eli Lilly and COM 532457108 197,100 -82,380 -29.48 32,360 -16.53 0.7442
2020-05-13 2020-03-31 13F Eli Lilly and COM 532457108 279,480 -68,845 -19.76 38,769 -15.31 1.0966
2020-02-13 2019-12-31 13F Eli Lilly and COM 532457108 348,325 53,950 18.33 45,780 39.06 0.9645
2019-11-14 2019-09-30 13F Eli Lilly and COM 532457108 294,375 294,375 32,920 0.7418
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.